文献速递中医内科中药与中成药合理使用

菊花富集黄酮部位对高尿酸血症模型的影响及机制

The impact of chrysanthemi indici flos-enriched flavonoid part on the model of hyperuricemia based on inhibiting synthesis and promoting excretion of uric acid.
PubMed 文献 · J Ethnopharmacol · 2024-06-24

本研究探讨菊花富集黄酮部位(CYM.E)防治高尿酸血症(HUA)的疗效及其对尿酸转运蛋白的影响。采用腺嘌呤和氧嗪酸钾诱导小鼠HUA模型,给予不同剂量CYM.E及别嘌醇,检测血尿酸、肝肾功能、血脂及肾脏转运蛋白表达。结果显示CYM.E可降低血尿酸、改善肝肾功能和血脂紊乱,抑制肝脏XOD和ADA活性,调节肾脏尿酸转运蛋白表达,从而抑制尿酸生成并促进排泄。

要点

  • CYM.E可降低HUA小鼠血尿酸、BUN、CR水平并改善肝肾功能。
  • CYM.E抑制肝脏XOD和ADA活性,减少尿酸生成。
  • CYM.E下调肾脏URAT1、GLUT9、OAT4表达,上调OAT1、OAT3、ABCG2表达,促进尿酸排泄。

核心结论

  • CYM.E通过抑制尿酸生成和促进尿酸排泄发挥降尿酸作用,并改善HUA小鼠肝肾功能及脂代谢紊乱。

研究设计与样本

  • 采用腺嘌呤和氧嗪酸钾诱导小鼠HUA模型,设别嘌醇10 mg/kg组及CYM.E 30、60、90 mg/kg剂量组进行干预。

主要发现

  • CYM.E中木犀草苷含量约为32.77%。
  • CYM.E降低HUA小鼠血浆UA、BUN、CR水平及血清ALT、AST活性,并减轻肾脏组织病理损伤。
  • CYM.E降低血浆TC、TG、LDL-c水平,改善脂代谢紊乱。
  • CYM.E抑制肝脏XOD和ADA活性,降低肾脏GLUT9 mRNA表达,抑制URAT1、GLUT9、OAT4蛋白表达,增加OAT1、OAT3、ABCG2的mRNA和蛋白表达。

临床怎么用

  • 菊花富集黄酮部位可能通过多靶点调节尿酸转运蛋白,为高尿酸血症的中药干预提供实验依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: In recent years, in addition to hypertension, hyperglycemia, and hyperlipidemia, the prevalence of hyperuricemia (HUA) has increased considerably. Being the fourth major health risk factor, HUA can affect the kidneys and cardiovascular system. Chrysanthemi Indici Flos is a flavonoid-containing traditional Chinese patent medicine that exhibits a uric acid (UA)-lowering effect. However, the mechanisms underlying Chrysanthemi Indici Flos-enriched flavonoid part (CYM.E) mediated alleviation of HUA remain unelucidated. AIM OF THE STUDY: This study aimed to elucidate the efficacy of CYM.E in preventing and treating HUA and its specific effects on UA-related transport proteins, to explore possible mechanism. METHODS: The buddleoside content in CYM.E was determined through high-performance liquid chromatography. HUA was induced in mice models using adenine and potassium oxonate. Subsequently, mice were administered 10 mg/kg allopurinol, and 30, 60, and 90 mg/kg CYM.E to evaluate the effects of CYM.E on the of HUA mice model. Herein, plasma uric acid (UA), creatinine (CR), blood urea nitrogen (BUN), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) contents, along with serum alanine aminotransferase (ALT), and aspartate aminotransferase (AST) activities were measured. Additionally, xanthine oxidase (XOD) and adenosine deaminase (ADA) activities in the liver were determined. The histomorphologies of the liver and kidney tissues were examined through hematoxylin and eosin staining. The messenger RNA (mRNA) expression of facilitated glucose transporter 9 (GLUT9), organic anion transporter (OAT)1, OAT3, and adenosine triphosphate binding cassette subfamily G2 (ABCG2) in the kidney was assessed by real-time quantitative polymerase chain reaction. Furthermore, the expression of urate transporter 1 (URAT1), GLUT9, OAT1, and OAT3 in the kidney, OAT4, and ABCG2 proteins was determined by immunohistochemistry and western blotting. RESULTS: The buddleoside content in CYM.E was approximately 32.77%. CYM.E improved body weight and autonomous activity in HUA mice. Additionally, it reduced plasma UA, BUN, and CR levels and serum ALT and AST activities, thus improving hepatic and renal functions, which further reduced the plasma UA content. CYM.E reduced histopathological damage to the kidneys. Furthermore, it lowered plasma TC, TG, and LDL-c levels, thereby improving lipid metabolism disorder. CYM.E administration inhibited hepatic XOD and ADA activities and reduced the mRNA expression of renal GLUT9. CYM.E inhibited the protein expression of renal URAT1, GLUT9, and OAT4, and increased the mRNA and protein expression of renal OAT1, OAT3, and ABCG2. Altogether, these results show that CYM.E could inhibit the production and promote reabsorption of UA and its excretion.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Jiao L, Wang R, Dong Y, et al. The impact of chrysanthemi indici flos-enriched flavonoid part on the model of hyperuricemia based on inhibiting synthesis and promoting excretion of uric acid. J Ethnopharmacol. 2024. PMID: 38925319. doi:10.1016/j.jep.2024.118488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。